Belsomra (Suvorexant) Titration in Renal Impairment: What Women Need to Know

Why Renal Impairment Changes the Conversation for Women

Kidney disease is not a gender-neutral condition. Women develop chronic kidney disease (CKD) at rates comparable to men, yet are underrepresented in nephrology clinical trials and often receive less aggressive treatment for both their CKD and their sleep disorders. At the same time, insomnia affects women disproportionately across the lifespan. Roughly 40% of women with CKD stages 3-5 report clinically significant insomnia compared with approximately 25% of the general adult population.

Why Women With Kidney Disease Lose Sleep

The mechanisms are layered. Uremic toxin accumulation disrupts circadian signaling. Restless legs syndrome, which is twice as prevalent in women as in men, worsens in CKD. Perimenopausal vasomotor symptoms add nocturnal awakenings on top of uremia-related disruption. For a woman managing dialysis, hormonal flux, and chronic fatigue, insomnia is not a minor complaint. It compounds cardiovascular risk, worsens cognitive function, and erodes quality of life.

Where Suvorexant Fits

Suvorexant works by blocking orexin receptors OX1R and OX2R, which are the receptors that drive wakefulness. This mechanism is genuinely different from benzodiazepines and Z-drugs, which carry outsized risks in women with CKD because of their renal clearance dependence and higher fall-and-fracture risk. Suvorexant offers a CKD-friendly pharmacokinetic profile, but that does not mean titration is simple, particularly in women.

Suvorexant Pharmacokinetics in Renal Impairment: The Full Picture

The FDA-approved prescribing information for suvorexant states that no dose adjustment is required in patients with mild, moderate, or severe renal impairment, including those on dialysis. This is the clinical bottom line. The reasoning matters, though, because it shapes how you and your clinician titrate safely.

Why the Kidneys Are Not the Main Story

Suvorexant is metabolized almost entirely by hepatic CYP3A4 enzymes. Renal clearance accounts for a negligible fraction of total drug elimination. In a dedicated pharmacokinetic study referenced in the label, suvorexant exposure (AUC and Cmax) in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) was not meaningfully different from matched controls with normal kidney function. Protein binding is approximately 99%, so dialysis does not remove clinically significant amounts of the drug.

This is reassuring. A woman on hemodialysis three times per week does not need to time her suvorexant dose around her dialysis schedule, and she does not need a reduced dose purely because of her kidney function.

What Does Change in CKD

Several indirect factors do shift the risk calculation for women with renal disease.

Polypharmacy burden. Women with CKD stages 3-5 take an average of 8-10 medications. CYP3A4 inhibitors (including fluconazole, diltiazem, and verapamil, all commonly used in women with CKD) can increase suvorexant exposure substantially. When a moderate CYP3A4 inhibitor is co-prescribed, the effective suvorexant dose may behave closer to a higher dose than the milligram number on the label suggests.

Altered protein binding. Uremia reduces albumin binding capacity for many drugs. Although suvorexant binds primarily to non-albumin proteins, clinicians should remain alert to any shift in free-drug fraction, particularly in women with nephrotic syndrome or severe hypoalbuminemia.

Central nervous system sensitivity. Women in general metabolize CYP3A4 substrates differently than men at baseline. Add the neurological effects of uremia and the possibility of concurrent sleep-disordered breathing (common in CKD), and next-morning sedation becomes a genuine clinical concern even at the 10 mg starting dose.

The Standard Titration Schedule and How to Adapt It for CKD

The WomanRx Renal-Adapted Titration Framework below synthesizes the FDA label guidance with the pharmacokinetic data from the key SUNRISE 1 and SUNRISE 2 trials and applies it specifically to women with CKD.

Step 1: Start at 10 mg, Every Time

Start at 10 mg regardless of your stage of kidney disease. The SUNRISE trials enrolled patients at 10 mg and 20 mg. The 10 mg dose improved sleep onset latency by approximately 8 minutes and total sleep time by roughly 22 minutes versus placebo in the phase 3 data. These are modest numbers on paper, but they were measured objectively with polysomnography and were statistically significant.

For women with CKD, 10 mg is the correct entry point, period. Even though the label does not require a lower dose, starting lower (5 mg) is off-label and not supported by efficacy data. The label does not offer a 5 mg tablet for a reason.

Step 2: Assess at 7-14 Days Before Titrating Up

Before moving to 20 mg, you need an honest assessment of two things: Did sleep improve? And are you experiencing next-morning sedation?

Ask yourself these questions at day 7 and day 14.

• Do you feel fully alert within 60-90 minutes of waking?
• Have you noticed any difficulty with driving, balance, or word-finding?
• Has your sleep onset improved or your nighttime awakenings decreased?

If sedation is present and sleep benefit is partial, wait another two weeks before considering an increase. Women with CKD who are also taking a CYP3A4 inhibitor should discuss with their prescriber whether an upward titration is appropriate at all, given the pharmacokinetic amplification.

Step 3: Move to 20 mg Only if the Benefit-Risk Balance Favors It

The FDA label sets 20 mg as the maximum dose. In the SUNRISE trials, the 20 mg dose showed a small additional benefit over 10 mg but also a higher rate of somnolence and sleep paralysis. For women with CKD on polypharmacy, 20 mg may produce an effective drug exposure equivalent to a higher dose due to CYP3A4 inhibitor co-administration. Your clinician should review your full medication list before approving a titration step.

When to Stay at 10 mg Indefinitely

Stay at 10 mg if:

• You take a moderate or strong CYP3A4 inhibitor (fluconazole, diltiazem, verapamil, erythromycin, grapefruit-containing medications)
• You have hepatic impairment in addition to CKD (the label contraindicates suvorexant in severe hepatic impairment)
• You are over 65 years old with CKD and additional fall risk
• You drive commercially or operate heavy machinery

Women Across Life Stages: Who Has CKD and Insomnia Together?

Reproductive Years (Ages 18-40)

Women with autoimmune-driven CKD (lupus nephritis, IgA nephropathy) often fall in this age group. Insomnia in this demographic frequently overlaps with pain, anxiety, and corticosteroid use, all of which can worsen sleep architecture independently. Suvorexant has not been studied in younger women with autoimmune CKD, and the interaction between immunosuppressants (many of which are CYP3A4 substrates or inhibitors) and suvorexant deserves careful pharmacist review before prescribing.

Trying to Conceive and Pregnancy

Do not take suvorexant if you are trying to conceive or are pregnant. See the dedicated pregnancy section below. This is non-negotiable.

Perimenopause (Typically Ages 45-55)

This is the highest-risk life stage for the combination of new-onset CKD and worsening insomnia. Estrogen decline accelerates glomerular filtration rate decline in women with pre-existing kidney disease. Vasomotor symptoms affect up to 80% of perimenopausal women, and nocturnal hot flashes disrupt sleep architecture in ways that mimic the sleep fragmentation of CKD. A perimenopausal woman presenting with insomnia and CKD may benefit from both suvorexant and hormonal evaluation. The Menopause Society notes that menopausal hormone therapy (MHT) itself may improve sleep, which should be weighed before adding a sleep medication.

Perimenopausal women should also know that suvorexant's half-life of approximately 12 hours means next-morning sedation is a real risk when vasomotor symptoms cause early waking after a late dose.

Postmenopause

Postmenopausal women have the highest rates of both CKD and chronic insomnia. Bone loss, fall risk, and cognitive changes in this group make sedation risk more consequential. Starting at 10 mg and staying there is usually the right strategy for postmenopausal women with CKD. The 20 mg dose should be reserved for situations where 10 mg demonstrably fails and there are no compounding risk factors.

Pregnancy, Lactation, and Contraception: Required Reading

Pregnancy

Avoid suvorexant during pregnancy. The FDA prescribing label reports that animal reproductive studies at doses producing exposures several times higher than the human therapeutic dose showed adverse effects on fetal development. There are no adequate, well-controlled studies in pregnant women. Suvorexant carries no formal FDA Pregnancy Category under the current labeling system (the letter categories were retired in 2015), but the human data are essentially absent.

If you discover you are pregnant while taking suvorexant, stop the medication and contact your obstetrician and your sleep medicine clinician promptly. CKD in pregnancy requires its own specialist team regardless of sleep medication status.

For women of reproductive age with CKD who are sexually active, reliable contraception is strongly advised while taking suvorexant, not because it is a known teratogen on the level of, for example, valproate or isotretinoin, but because the absence of human safety data makes an informed risk assessment impossible.

Lactation

Suvorexant transfer into human breast milk has not been studied. The FDA label advises that the drug's effects on a breastfed infant are unknown. Given suvorexant's high lipophilicity and the fact that orexin receptors are present in neonatal brain tissue, caution is warranted. Postpartum women with CKD who are breastfeeding should discuss alternative insomnia strategies with their care team. Behavioral interventions, specifically Cognitive Behavioral Therapy for Insomnia (CBT-I), carry no lactation risk and are endorsed as first-line by ACOG and the Menopause Society for sleep disturbance.

Contraception Requirement

There is no mandatory contraception requirement attached to suvorexant prescriptions by regulatory bodies, unlike drugs such as isotretinoin or thalidomide. A clinician who is well-informed, though, will discuss reliable contraception with any woman of reproductive potential who is starting suvorexant, particularly given the absence of human pregnancy data.

Drug Interactions That Matter More in Women With CKD

Women with CKD are prescribed a wide range of medications that interact with suvorexant's metabolism. The following interactions are clinically significant and change the effective dose.

CYP3A4 Inhibitors: Increase Suvorexant Exposure

The FDA label states that co-administration with strong CYP3A4 inhibitors (such as ketoconazole) is not recommended. With moderate inhibitors, the label recommends starting at 5 mg and not exceeding 10 mg. In clinical practice, several drugs commonly used in women with CKD fall into the moderate inhibitor category.

• Diltiazem (a calcium channel blocker widely used for hypertension in CKD)
• Verapamil (same class)
• Fluconazole (antifungal, commonly prescribed for vaginal candidiasis that increases in frequency with diabetes and CKD)
• Erythromycin and clarithromycin (macrolide antibiotics)

If you take any of these, your starting suvorexant dose should be 5 mg, even though a 5 mg tablet does not exist. In practice, this means the 10 mg tablet may be split at your clinician's discretion, with the understanding that scored tablets are required for accurate splitting. Discuss this specifically with your prescriber and pharmacist.

CYP3A4 Inducers: May Reduce Suvorexant Efficacy

Rifampin and other strong inducers substantially reduce suvorexant plasma levels. Women with CKD who are on rifampin for tuberculosis or other indications may find suvorexant ineffective at standard doses, and increasing the dose beyond 20 mg is not approved.

CNS Depressants: Additive Sedation Risk

Combining suvorexant with other CNS depressants, including opioids, gabapentin, and benzodiazepines, increases next-morning impairment risk. Gabapentin is commonly prescribed for uremic pruritus and restless legs in CKD. This specific combination (suvorexant plus gabapentin in a woman with CKD) is not studied in clinical trials, and the FDA label advises dose adjustment or avoidance of concomitant CNS depressants.

Evidence Gaps: What We Do Not Know for Women With CKD

Honest medicine requires naming what is missing. The SUNRISE 1 and SUNRISE 2 key trials enrolled approximately 1,000 participants each, but the proportion with CKD was small and not stratified by sex. Women were included but not analyzed as a separate subgroup for pharmacokinetics or efficacy in kidney impairment. The dedicated renal pharmacokinetic substudy referenced in the FDA label used healthy volunteers with renal impairment, not women with CKD who also had the polypharmacy burden, hormonal changes, and comorbidities typical of real clinical practice.

"Women have been historically underrepresented in sleep pharmacology trials," notes the 2023 NIH Office of Research on Women's Health strategic plan, which specifically calls for sex-stratified analyses in clinical trials of CNS-active agents. Until those data exist, every recommendation for women with CKD taking suvorexant is extrapolated from broader population data, not directly studied.

Sex differences in orexin signaling are biologically real. Animal studies show that female rodents have higher OX2R receptor density in sleep-relevant hypothalamic regions, suggesting women may have a different dose-response relationship to orexin receptor antagonists than men. This has not been confirmed in a human trial powered for sex-stratified analysis.

Who This Drug Is Right For, and Who Should Look Elsewhere

Women Who May Benefit From Suvorexant With CKD

• Perimenopausal or postmenopausal women with CKD stages 1-5 or ESRD whose insomnia has not responded to CBT-I alone
• Women who have failed or cannot tolerate Z-drugs (zolpidem, eszopiclone) due to residual sedation, tolerance, or renal clearance concerns
• Women with a history of substance use disorder where a non-benzodiazepine, non-GABAergic mechanism is preferred
• Women whose insomnia features predominantly sleep-maintenance problems (frequent awakenings, early morning waking) rather than purely sleep-onset difficulty, as suvorexant has been shown to address both in polysomnographic studies

Women Who Should Avoid Suvorexant

• Pregnant women or those actively trying to conceive
• Breastfeeding women
• Women with narcolepsy (orexin blockade may worsen cataplexy)
• Women with severe hepatic impairment (Child-Pugh C), where the label contraindication applies
• Women who cannot safely avoid driving or operating machinery within 8 hours of a dose
• Women taking strong CYP3A4 inhibitors where alternative insomnia approaches are available

First-Line Before Medication: CBT-I Matters for Women With CKD

Both the ACOG and the American Academy of Sleep Medicine position Cognitive Behavioral Therapy for Insomnia (CBT-I) as the first-line treatment for chronic insomnia in adults. This applies to women with CKD. CBT-I delivered via telehealth has demonstrated efficacy comparable to in-person delivery and carries none of the drug interaction or sedation risks relevant to women with kidney disease. A 2022 meta-analysis in JAMA Internal Medicine found that digital CBT-I reduced sleep onset latency and wake after sleep onset with effect sizes similar to those seen with pharmacotherapy at four to eight weeks.

Suvorexant is appropriate when CBT-I has been tried and is insufficient, not as a replacement for it. For a woman with CKD, starting CBT-I first also preserves the option of using suvorexant at 10 mg, its lowest and safest dose, rather than escalating prematurely.

Monitoring After Starting Suvorexant in CKD

Once you begin suvorexant at 10 mg, structured follow-up protects you from the drug's most clinically significant risks.

Week 2 check-in. Assess morning alertness, any episodes of sleep paralysis or hypnagogic hallucinations (which the SUNRISE trials recorded in approximately 1-2% of patients at 10-20 mg), and any new falls or near-falls. Women with CKD who are also anemic or orthostatic have a compounded fall risk.

Month 1 medication review. Any new prescriptions added since suvorexant started should be checked for CYP3A4 interactions. A pharmacist review is the most reliable safety check.

Ongoing. If your kidney function declines and you transition from CKD stage 3 to stage 5, or from CKD to dialysis, your suvorexant dose does not change based on the label. Your overall medication burden may change substantially, though, and the interaction field should be reassessed at each transition.

Women should also monitor for worsening mood. Suvorexant carries a label warning for complex sleep behaviors (sleepwalking, sleep-driving) and a class-level caution for worsening depression. Postmenopausal women with CKD, who have elevated baseline rates of depression, deserve explicit monitoring for mood changes within the first 30 days of therapy.